Q1 2022 Results

Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in registration Solid Tumors Code VDT482 Name Others Code Mechanism Indication(s) tislelizumab PD1 inhibitor 2L ESCC Non-small cell lung cancer Name Mechanism Global Health Indication(s) SKO136 ensovibep Multi-specific DARPin Corona virus infection Appendix Innovation: Clinical trials Hematology Code CTL019 Name KymriahⓇ INC424 Jakavi® References Abbreviations 2 lead indications Lead indication Mechanism CD19 CAR-T JAK1/2 inhibitor Indication(s) r/r Follicular lymphoma Acute GVHD Chronic GVHD 41 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation